Welcome to the 4^th Cytokine-Based Drug Development Summit

New doors opened for Cytokine drug developers to treat diseases both in and beyond oncology with novel masking and tissue targeting mechanisms and the abundance of preclinical and clinical efficacy data as more companies get additional funding to boost their pipelines.

This year's summit was the time to join forces with key decision-makers including Sanofi, Moderna, Xencor, CytomX and more at the 4^th Cytokine-Based Drug Development Summit, the only industry focused event exclusively addressing discovery, translational and reverse translational challenges.

This industry-led conference equipped attendees with the latest scientific insights to develop a cytokine drug with reduced toxicities, enabling our audience to dose at the right level and witness greater clinical benefit to patients.

With a focus on Interleukin-2 (IL-2), Interleukin 12 (IL-12), Interleukin 7 (IL-7) and more across oncology, attendees learned new approaches to limiting toxicities, how to develop an accurate and reliable preclinical model, as well as lessons from clinical development to inform future design principles.